Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B A Tjoa

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Prostate|July 1, 1999
Follow-up evaluation of a phase II prostate cancer vaccine trialB A Tjoa, S J Simmons, A Elgamal, et al.
The Prostate|December 1, 1999
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patientsG P Murphy, P Snow, S J Simmons, et al.
The Prostate|May 27, 1999
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trialS J Simmons, B A Tjoa, M Rogers, et al.
The Prostate|April 30, 1999
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatmentG P Murphy, B A Tjoa, S J Simmons, et al.
The Prostate|May 6, 1998
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)M L Salgaller, P A Lodge, J G McLean, et al.
The Prostate|September 1, 1997
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptidesB A Tjoa, S J Erickson, V A Bowes, et al.
The Canadian Journal of Urology|June 1, 1997
Cancer immunotherapy for prostate cancerB. A. Tjoa, S. J. Erickson, V. A. Bowes, et al.
The Prostate|April 1, 1996
Measurement of prostate-specific membrane antigen in the serum with a new antibodyG P Murphy, W T Tino, E H Holmes, et al.
The Prostate|July 3, 1998
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptidesB A Tjoa, S J Simmons, V A Bowes, et al.
The Prostate|February 11, 1999
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseG P Murphy, B A Tjoa, S J Simmons, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Prostate|July 1, 1999
Follow-up evaluation of a phase II prostate cancer vaccine trialB A Tjoa, S J Simmons, A Elgamal, et al.
The Prostate|December 1, 1999
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patientsG P Murphy, P Snow, S J Simmons, et al.
The Prostate|May 27, 1999
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trialS J Simmons, B A Tjoa, M Rogers, et al.
The Prostate|April 30, 1999
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatmentG P Murphy, B A Tjoa, S J Simmons, et al.
The Prostate|May 6, 1998
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)M L Salgaller, P A Lodge, J G McLean, et al.
The Prostate|September 1, 1997
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptidesB A Tjoa, S J Erickson, V A Bowes, et al.
The Canadian Journal of Urology|June 1, 1997
Cancer immunotherapy for prostate cancerB. A. Tjoa, S. J. Erickson, V. A. Bowes, et al.
The Prostate|April 1, 1996
Measurement of prostate-specific membrane antigen in the serum with a new antibodyG P Murphy, W T Tino, E H Holmes, et al.
The Prostate|July 3, 1998
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptidesB A Tjoa, S J Simmons, V A Bowes, et al.
The Prostate|February 11, 1999
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseG P Murphy, B A Tjoa, S J Simmons, et al.
Pageof 2